NasdaqGS:ALNYBiotechs
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY)
In late July 2026, Alnylam Pharmaceuticals cut its full-year TTR product sales guidance after reassessing growth expectations for the ATTR-CM market, prompting a law firm to continue investigating potential federal securities law violations related to the company’s disclosures.
This combination of lowered product expectations and legal scrutiny may influence how investors view the resilience and risks of Alnylam’s RNAi-focused business model.
We’ll now examine how the reduced TTR sales...